Nachrichten zur ChemoCentryx Aktie

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.…

ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020....…

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript

CCXI earnings call for the period ending September 30, 2020....…

ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the…

Recap: ChemoCentryx Q3 Earnings

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down…

ChemoCentryx, Inc.: 10-Q Report

10-Q...…

ChemoCentryx, Inc.: 8-K Report

8-K...…

ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis

-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal…

ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal…

Pharma - Vifor Fresenius macht mit Medikament weiteren Schritt bei EU-Zulassung

Das Gemeinschaftsunternehmen Vifor Fresenius Medical Care Renal Pharma (VFMCRP) kommt zusammen mit seinem Partner ChemoCentryx bei den Zulassungsplänen für Avacopan…

ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys…

ChemoCentryx downgraded to neutral from overweight at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx, Inc.: 8-K Report

8-K...…

ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III…

Final Trades: AT&T, Jumia Technologies, Chemocentryx, General Motors

The “Halftime Report” traders give their top picks to watch for the second half....…

ChemoCentryx (CCXI) - Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CCXI To Face FDA In April, CRDF Soars On Colorectal Cancer Trial Data, VCNX In Deal With MRK

Todays Daily Dose brings you news about ChemoCentryxs regulatory catalyst in July, Checkpoints $20 million bought deal offering, CytRxs potential…

ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.…

ChemoCentryx, Inc.: 8-K Report

8-K...…

ChemoCentryx Inc (CCXI) Q2 2020 Earnings Call Transcript

CCXI earnings call for the period ending June 30, 2020....…

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx (CCXI) Q2 Earnings and Revenues Surpass Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the…

ChemoCentryx, Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx, Inc.: 10-Q Report

10-Q...…

ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys…

ChemoCentryx files U.S. avacopan application for blood vessel inflammation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis

MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company…

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Companys orally administered small molecule…

ChemoCentryx prices equity offering at $58

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Prices Public Offering of Common Stock

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced…

ChemoCentryx files for mixed shelf

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ChemoCentryx Announces Proposed Public Offering of Common Stock

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced…

ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses

Pivotal trial demonstrated avacopans statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy Pivotal trial demonstrated…

ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and…